Yıl: 2001 Cilt: 31 Sayı: 4 Sayfa Aralığı: 329 - 335 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation

Öz:
Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation
Anahtar Kelime: TBARS Cystatins Lipid Peroxidation Alzheimer Disease Thiobarbituric Acid Reactive Substances Oxidative Stress

Konular: Cerrahi

-

Öz:
Growing data suggest oxidative stress contributes to the pathogenesis of Alzheimer's disease (AD). The objective of this study was to assess the value of antioxidant potential (AOP), antioxidant status (AOS) and thiobarbituric acid reactive substances (TBARS) and the cysteine protease inhibitor Cystatin C that plays a role in the processing of amyloid as clinical markers of AD in peripheral circulation and to find out the agreement limits of AOP and AOS as clinical laboratory tests. To do this, 21 severely demented patients fitting the DSM-IV diagnostic criteria for Alzheimer's type dementia as well as through minimental state examination were compared to 20 age-matching healthy controls with respect to their serum AOP, AOS, Cystatin C and TBARS levels. The under-curve area detected from ROC curves for TBARS, AOS, AOP and Cystatin C were 0.801, 0.622, 0.475 and 0.65 respectively. Altman and Bland analysis showed that the values obtained by the AOP assay were 0.0149-0.04664 with a mean of 0.03081 units higher than those values obtained via AOS assay, indicating a low level of agreement. In addition, Pearson's correlation testing showed a significant negative correlation between AOP and AOS (r=0.479, p<0.01). As a conclusion, among the tests investigated in this study, TBARS may be used as a dependable peripheral marker of AD with a sensitivity of 0.85 and a specificity of 0.6 at the cut-off point of 0.77 nmol/ml. AOS should be preferred to AOP as a marker with a specificity and sensitivity of 0.7 at the cut-off point of 0.011nmol/ml. Further studies may be undertaken to reveal the pathogenetic relation of oxidant stress and the processing of amyloid ß.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1. Simonian NA, Coyle ST. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36: 83- 106, 1996
  • 2. Multhaup G. Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, Beyreuther K. Reactive oxygen species and AlzheimerÕs Disease. Biochemical Pharmacology 54; 533-39, 1997
  • 3. Yankner B, Dawes L, Fisher S, Villa- Kamaroff L, Oster-Granite M, et al. Neurotoxicity of a fragment of the amyloid precursor associated with AlzheimerÕs disease. Science 245; 417- 20, 1989
  • 4. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid b protein toxicity. Biochem Biophy Res Commun 186; 944-50, 1992 5. Behl C, Davis J, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid b protein toxicity. Cell 77; 817-27, 1994
  • 6. Selkoe D. The molecular pathology of Alzheimer's disease. Neuron 6;487- 498, 1991
  • 7. Dyrks T, Dyrks E, Hartman T, Masters C, Beyreuther K. Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal catalyzed oxidation. J Biol Chem 267; 18210-17, 1992
  • 8. Palmer A, Burris M. Selective increase in lipid peroxidation in the inferior temporal cortex in AlzheimerÕs disease. Brain Res 645; 338-42, 1994
  • 9. Markesbery WR. Oxidative stress hypothesis in AlzheimerÕs disease. Free Radic Biol Med 23; 134-47, 1997
  • 10. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, Kokmen E. No evidence for systemic oxidant stress in ParkinsonÕs or AlzheimerÕs disease. Mov Disord 10; 566-73, 1995
  • 11. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma antioxidant status in subjects with AlzheimerÕs disease and vascular dementia. Int J Geriatr Psychiatry 13; 840-5, 1998
  • 12. De Leo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, Filippini V, Galeotti T, Masullo C. Oxidative stress and overexpression of mangenese superoxide dismutase in patients with AD. Nurosci Lett 250; 173-6, 1998
  • 13. Davidson P, Ekman R, Blennow K. A new procedure for detecting brain specific proteins in cerebrospinal fluid. Journal of Neural Transmission 104; 711-20, 1997
  • 14. Davidson P, Ekman R, Blennow K. A new procedure for detecting brain specific proteins in cerebrospinal fluid. Journal of Neural Transmission 104: 711-720, 1997
  • 15. Malloy MF, Cummings JL, Coffey CE, Duffy J, Fink M, Lauterbach EC, Lovell M, Royall D, Salloway S. Cognitive screening instruments in neuropsychiatry: a report of the committee on research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 9: 189- 97, 1997
  • 16. Durak I, Karabacak HI, BŸyŸkkoak S, ‚imen B, Kamaz M, …meroÛlu E, …ztŸrk HS. Impaired Antioxidant Defense System in Kidney Tissues from Rabbits Treated with Cyclosporine. Nephron 78; 207-11, 1998
  • 17. Miller N, Rice-Evans C, Davies MJ, Gopinathan V and Milner A.A Novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clinical Science 84;407-12, 1993
  • 18. Van Ye TM, Roza AM, Pieper GM, Henderson JRJ, Johnson CP, Adams MB. Inhibition of intestinal lipid peroxidation does not minimize morphological damage. J Surg Res 55;553-8, 1993
  • 19. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function: a review. Clin Chem Lab Med 37; 389-95, 1999
  • 20. Bland JM, Altman DG. Statistical methods for assessing agreement between measurement Biochim Clin 11:399-404, 1987
  • 21. Richardson JS. Free radicals in genesis of AlzheimerÕs disease. Ann NY Acad Sci 685;73-6, 1993
  • 22. Marcus DL, Thomas C, Rodrigues C, Simberkoff T, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in AlzheimerÕs disease. Exp Neurol 150;40-4, 1998
  • 23. Arai H. Biological markers for the clinical diagnosis of AlzheimerÕs Disease. Tohoku J Exp. Med 179; 65- 79, 1996
  • 24. Valanti G. Neuropeptide changes in Dementia: Pathogenetic Implications and diagnostic value. Gerontology 42: 241-256, 1996
  • 25. Wahlund LO. Biological markers and diagnostic investigations in AlzheimerÕs disease. Acta Neurol Scand; Supplement 165: 85-91, 1996
  • 26. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma antioxidant status in subjects with AlzheimerÕs disease and vascular dementia. Int J Geriatr Psychiatry 13;840-5, 1998
  • 27. Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B. Low plasma Vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 13;749-54, 1998
APA AKBAY A, aydemir m, DEMİRTAŞ S, TUNCER T, CANBOLAT O, GENÇ Y (2001). Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. , 329 - 335.
Chicago AKBAY Ayşegül,aydemir makbule çiğdem,DEMİRTAŞ Selda,TUNCER Turan Engin,CANBOLAT Orhan,GENÇ Yasemin Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. (2001): 329 - 335.
MLA AKBAY Ayşegül,aydemir makbule çiğdem,DEMİRTAŞ Selda,TUNCER Turan Engin,CANBOLAT Orhan,GENÇ Yasemin Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. , 2001, ss.329 - 335.
AMA AKBAY A,aydemir m,DEMİRTAŞ S,TUNCER T,CANBOLAT O,GENÇ Y Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. . 2001; 329 - 335.
Vancouver AKBAY A,aydemir m,DEMİRTAŞ S,TUNCER T,CANBOLAT O,GENÇ Y Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. . 2001; 329 - 335.
IEEE AKBAY A,aydemir m,DEMİRTAŞ S,TUNCER T,CANBOLAT O,GENÇ Y "Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation." , ss.329 - 335, 2001.
ISNAD AKBAY, Ayşegül vd. "Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation". (2001), 329-335.
APA AKBAY A, aydemir m, DEMİRTAŞ S, TUNCER T, CANBOLAT O, GENÇ Y (2001). Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. Turkish Journal of Medical Sciences, 31(4), 329 - 335.
Chicago AKBAY Ayşegül,aydemir makbule çiğdem,DEMİRTAŞ Selda,TUNCER Turan Engin,CANBOLAT Orhan,GENÇ Yasemin Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. Turkish Journal of Medical Sciences 31, no.4 (2001): 329 - 335.
MLA AKBAY Ayşegül,aydemir makbule çiğdem,DEMİRTAŞ Selda,TUNCER Turan Engin,CANBOLAT Orhan,GENÇ Yasemin Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. Turkish Journal of Medical Sciences, vol.31, no.4, 2001, ss.329 - 335.
AMA AKBAY A,aydemir m,DEMİRTAŞ S,TUNCER T,CANBOLAT O,GENÇ Y Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. Turkish Journal of Medical Sciences. 2001; 31(4): 329 - 335.
Vancouver AKBAY A,aydemir m,DEMİRTAŞ S,TUNCER T,CANBOLAT O,GENÇ Y Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation. Turkish Journal of Medical Sciences. 2001; 31(4): 329 - 335.
IEEE AKBAY A,aydemir m,DEMİRTAŞ S,TUNCER T,CANBOLAT O,GENÇ Y "Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation." Turkish Journal of Medical Sciences, 31, ss.329 - 335, 2001.
ISNAD AKBAY, Ayşegül vd. "Antioxidant status, lipid peroxidation products and cystatin C as potential clinical markers of Alzheimer's disease in systemic circulation". Turkish Journal of Medical Sciences 31/4 (2001), 329-335.